More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$10.06B
EPS
8.19
P/E ratio
46.6
Price to sales
3.95
Dividend yield
--
Beta
1.070338
Previous close
$382.41
Today's open
$383.05
Day's range
$374.81 - $383.05
52 week range
$236.73 - $396.23
show more
CEO
Norman Schwartz
Employees
7400
Headquarters
Hercules, CA
Exchange
New York Stock Exchange
Shares outstanding
26738175
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time. A live webcast and subsequent replay of the event will be available in the Investor Relation.
Business Wire • Sep 16, 2026

Bio-Rad: Favorable Read-Across From Investor Event
Bio-Rad Laboratories (BIO) remains a Buy, after my assessment of relevant corporate disclosures at the recent Wells Fargo Healthcare conference. Management targets long-term operating margins of 20%, with intermediate milestones in the mid-teens, outpacing consensus expectations. Margin drivers include cost rationalization, AI-driven efficiencies, and a shift toward higher-margin consumables revenue.
Seeking Alpha • Sep 10, 2026

Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha • Sep 9, 2026

Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research • Sep 3, 2026

Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.
Business Wire • Aug 31, 2026

Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Zacks Investment Research • Aug 21, 2026

Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
Zacks Investment Research • Aug 20, 2026

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Zacks Investment Research • Aug 10, 2026

Bio-Rad Laboratories Q2 Earnings Call Highlights
Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.
MarketBeat • Aug 5, 2026

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Bio-Rad Laboratories Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.